Abstract Number: 1598 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, a Non-Inflammatory Neuropsychiatric Syndrome In Systemic Lypus Erythematosus
Background/Purpose: Cognitive dysfunction (CD) affects 15 – 60% of SLE patients; nevertheless, its pathogenesis and predisposing factors are unknown. Objective: To identify factors associated with CD…Abstract Number: 1599 • 2013 ACR/ARHP Annual Meeting
High Proportion Of Intrathecal Ro52 SSA Antibodies In Neuropsychiatric Lupus Patients – Relations To Neuropsychiatric Manifestations
Background/Purpose: Neuropsychiatric (NP) manifestations in Systemic Lupus Erythematosus (SLE) are often associated with significant impact on quality of life and work capability. The underlying mechanisms…Abstract Number: 1600 • 2013 ACR/ARHP Annual Meeting
Anti-Ribosomal P Protein Antibodies Exacerbate Long-Term Prognosis In Patients With Diffuse Neuropsychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematous
Background/Purpose: Systemic lupus erythematous (SLE) is a chronic inflammatory disease characterized by the expression of a variety of autoantibodies. Although the comprehensive survival from the…Abstract Number: 1601 • 2013 ACR/ARHP Annual Meeting
The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as Interferon-α In Systemic Lupus Erythematosus
Background/Purpose: IgG-Immune complexes (IC) formed by CSF autoantibodies in patients with neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) has reported to stimulate the production of…Abstract Number: 1602 • 2013 ACR/ARHP Annual Meeting
Autoantibodies, Cytokines and Chemokines In Serum and Cerebrospinal Fluid Of SLE Patients With Cognitive Dysfunction
Background/Purpose: The nature and pathogenesis and cognitive dysfunction (CD) in patients with SLE is unkown.To determine the presence and levels of autoantibodies, cytokines and chemokines…Abstract Number: 1561 • 2013 ACR/ARHP Annual Meeting
Treat-To-Target In Systemic Lupus Erythematosus: Report From the T2T/SLE Working Party
Background/Purpose: The principle of treating-to-target has been applied successfully to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and…Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…Abstract Number: 1564 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data
Background/Purpose: Several studies suggest that the efficacy of influenza vaccination may be decreased in systemic lupus erythematosus (SLE). We performed a meta-analysis to assess systematically…Abstract Number: 1565 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Confirms Clinical Safety Of Herpes Zoster Vaccine
Background/Purpose: SLE patients have increased risk of Herpes Zoster (HZ). A live-attenuated vaccine is available for healthy persons > 50 years old, but its safety…Abstract Number: 1566 • 2013 ACR/ARHP Annual Meeting
Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Background/Purpose: The definitions of low disease activity state (LDAS) and remission as desirable treatment goals in rheumatoid arthritis have been widely applied in research and…Abstract Number: 1567 • 2013 ACR/ARHP Annual Meeting
Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study
Background/Purpose: A high incidence of trimethoprin-sulfamethoxazole (TMP/SMX) hypersensitivity is reported in patients with systemic lupus erythematosus (SLE), and reactions are often severe. Desensitization protocol is…Abstract Number: 1568 • 2013 ACR/ARHP Annual Meeting
A Comparative Study For High Prevalence Of A Positive Family History Of Systemic LUPUS Erythematosus In Juvenile-Onset Systemic LUPUS Erythematosus Versus Adult-Onset Disease
Background/Purpose: The pathogenesis of SLE is complex and poorly understood. Infectious triggers, immunological abnormalities, environmental factors and genetic background play a combined role in disease…Abstract Number: 1569 • 2013 ACR/ARHP Annual Meeting
The Accuracy Of The ICD-9 Code 710.0 To Identify a Cohort Of SLE Patients From The Electronic Medical Record
Background/Purpose: The electronic medical record (EMR) is increasingly used as a primary source of retrospective research data from large 'virtual cohorts' of patients. The accuracy…Abstract Number: 1570 • 2013 ACR/ARHP Annual Meeting
Maintenance Therapy With Taclorimus and Mizoribine Pulse In SLE
Background/Purpose: It was reported in 2008 that multitarget therapy, consisting of taclorimus (TAC), mycophenolate mofetil (MMF) and glucocorticoid, is effictive and safe in induction therapy…Abstract Number: 1571 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tacrolimus Combination Therapy During The Maintenance Phase Of Systemic Lupus Erythematosus
Background/Purpose: In Japan, a placebo-controlled clinical trial was undertaken to investigate the efficacy and safety of tacrolimus (TAC) for lupus nephritis. Based on the results…